Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Argus Health
Chinese Patent Office
Cipla
Novartis
Deloitte
Dow
Fish and Richardson
Covington
Healthtrust

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,085,553

« Back to Dashboard

Which drugs does patent 9,085,553 protect, and when does it expire?


Patent 9,085,553 protects XIIDRA and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 9,085,553

Title:LFA-1 inhibitor and methods of preparation and polymorph thereof
Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed. ##STR00001##
Inventor(s): Zeller; James Robert (Scottsdale, AZ), Venkatraman; Sripathy (Slingerlands, NY), Brot; Elisabeth C. A. (Albany, NY), Iyer; Subashree (Guilderland, NY), Hall; Michael (Albany, NY)
Assignee: SARCODE BIOSCIENCE, INC. (Brisbane, CA)
Application Number:13/950,807
Patent Claim Types:
see list of patent claims
Use; Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,085,553

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,708,303LFA-1 inhibitor and methods of preparation and polymorph thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,085,553

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2015523398► Subscribe
India847DEN2015► Subscribe
Hong Kong1210782► Subscribe
Hong Kong1210145► Subscribe
European Patent Office2877465► Subscribe
China104797574► Subscribe
South Korea20150067129► Subscribe
Australia2013295706► Subscribe
Canada2879982► Subscribe
Mexico2015001098► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Moodys
Daiichi Sankyo
Healthtrust
US Army
Novartis
Fish and Richardson
Farmers Insurance
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot